SPAGO.ST
Spago Nanomedical AB (publ) [SPAGO.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SPAGO.ST Stock Summary
Top 10 Correlated ETFs
SPAGO.ST
Top 10 Correlated Stocks
SPAGO.ST
In the News
SPAGO.ST Financial details
Company Rating
Neutral
Market Cap
78.38M
Income
-39.33M
Revenue
1.01M
Book val./share
2.57
Cash/share
0.88
Dividend
-
Dividend %
-
Employees
15
Optionable
No
Shortable
Yes
Earnings
-
P/E
-1.67
Forward P/E
-
PEG
-0.74
P/S
65.05
P/B
0.32
P/C
0.92
P/FCF
-1.65
Quick Ratio
16.63
Current Ratio
17.11
Debt / Equity
0.02
LT Debt / Equity
-
-
-
EPS (TTM)
-0.85
EPS next Y
-
EPS next Q
-
EPS this Y
105.37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
8.6%
Revenue last 5Y
69.62%
Revenue Q/Q
30.59%
EPS Q/Q
-52.17%
-
-
-
-
SMA20
-8.33%
SMA50
-8.33%
SMA100
8.45%
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-20%
ROC
-0.19%
Gross Margin
-1573%
Oper. Margin
-3891%
Profit Margin
-3890%
Payout
-
Shs Outstand
96.76M
Shs Float
72.67M
-
-
-
-
Target Price
-
52W Range
0.576-3.65
52W High
-
52W Low
-
RSI
54.67
Rel Volume
0.36
Avg Volume
105.63K
Volume
38.25K
Perf Week
7.71%
Perf Month
-3.34%
Perf Quarter
-2.41%
Perf Half Y
-6.9%
-
-
-
-
Beta
1.88317
-
-
Volatility
0.02%, 0.04%
Prev Close
6.58%
Price
0.81
Change
0%
SPAGO.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0.01 | 0.02 | |
| Net income per share | -0.95 | -0.68 | -0.95 | -0.69 | -1.43 | |
| Operating cash flow per share | -0.77 | -0.64 | -1 | -0.69 | -1.3 | |
| Free cash flow per share | -2.59 | -2.4 | -1.86 | -0.92 | -1.47 | |
| Cash per share | 3.03 | 1 | 0.57 | 1.04 | 1.92 | |
| Book value per share | 10.79 | 7.45 | 6.49 | 5.84 | 6.76 | |
| Tangible book value per share | 2.83 | 0.87 | 0.54 | 1.02 | 1.78 | |
| Share holders equity per share | 10.79 | 7.45 | 6.49 | 5.84 | 6.76 | |
| Interest debt per share | 0.03 | 0 | 0 | 0 | 0 | |
| Market cap | 87.4M | 181.24M | 318.16M | 232.64M | 131.13M | |
| Enterprise value | 57.09M | 164.77M | 306.01M | 204.19M | 78.67M | |
| P/E ratio | -9.24 | -16.34 | -15.74 | -12.29 | -3.36 | |
| Price to sales ratio | 1.86K | 0 | 10.61K | 680.24 | 198.69 | |
| POCF ratio | -11.31 | -17.24 | -14.95 | -12.4 | -3.69 | |
| PFCF ratio | -3.38 | -4.6 | -8.05 | -9.25 | -3.26 | |
| P/B Ratio | 0.81 | 1.48 | 2.31 | 1.46 | 0.71 | |
| PTB ratio | 0.81 | 1.48 | 2.31 | 1.46 | 0.71 | |
| EV to sales | 1.21K | 0 | 10.2K | 597.06 | 119.2 | |
| Enterprise value over EBITDA | -6.41 | -15.38 | -15.41 | -11 | -2.03 | |
| EV to operating cash flow | -7.39 | -15.68 | -14.37 | -10.88 | -2.21 | |
| EV to free cash flow | -2.21 | -4.18 | -7.75 | -8.12 | -1.96 | |
| Earnings yield | -0.11 | -0.06 | -0.06 | -0.08 | -0.3 | |
| Free cash flow yield | -0.3 | -0.22 | -0.12 | -0.11 | -0.31 | |
| Debt to equity | 0.04 | 0.03 | 0.02 | 0.02 | 0.04 | |
| Debt to assets | 0.03 | 0.03 | 0.02 | 0.02 | 0.04 | |
| Net debt to EBITDA | 3.4 | 1.54 | 0.61 | 1.53 | 1.36 | |
| Current ratio | 8.13 | 4.2 | 4.67 | 9.48 | 7.98 | |
| Interest coverage | -33.69 | 0 | 0 | 0 | 0 | |
| Income quality | 0.82 | 0.95 | 1.05 | 0.99 | 0.91 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 126.77 | 0 | 208.07 | 15.24 | 11.43 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.71 | 0.85 | 0.9 | 0.81 | 0.71 | |
| Capex to operating cash flow | 2.34 | 2.75 | 0.86 | 0.34 | 0.13 | |
| Capex to revenue | -385.23 | 0 | -607.13 | -18.67 | -7.01 | |
| Capex to depreciation | -64.66 | -76.78 | -51.02 | -17.64 | -12.31 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 15.16 | 10.65 | 11.79 | 9.55 | 14.75 | |
| ROIC | -0.18 | -0.12 | -0.17 | -0.18 | -0.47 | |
| Return on tangible assets | -0.29 | -0.6 | -1.4 | -0.61 | -0.7 | |
| Graham Net | 2.65 | 0.75 | 0.44 | 0.93 | 1.67 | |
| Working capital | 27.16M | 13.12M | 10.67M | 26.69M | 47.58M | |
| Tangible asset value | 28.28M | 14.25M | 11.5M | 27.77M | 48.65M | |
| Net current asset value | 27.16M | 13.12M | 10.67M | 26.69M | 47.58M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.34M | 2.11M | 1.34M | 726K | 2.39M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | -89.9 | -91.08 | -73.06 | 446.38 | 80.8 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | -4.06 | -4.01 | -5 | 0.82 | 4.52 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.09 | -0.09 | -0.15 | -0.12 | -0.21 | |
| Capex per share | -1.81 | -1.76 | -0.86 | -0.23 | -0.17 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0.01 | 0.01 | 0 | |
| Net income per share | -0.25 | -0.27 | -0.24 | -0.23 | -0.11 | |
| Operating cash flow per share | -0.24 | -0.29 | -0.27 | -0.23 | -0.12 | |
| Free cash flow per share | -0.24 | -0.41 | -0.27 | -0.23 | -0.12 | |
| Cash per share | 1.6 | 1.27 | 1 | 0.7 | 0.88 | |
| Book value per share | 4.76 | 4.49 | 4.25 | 5.11 | 2.57 | |
| Tangible book value per share | 1.49 | 1.18 | 0.93 | 1.86 | 0.86 | |
| Share holders equity per share | 4.76 | 4.49 | 4.25 | 5.11 | 2.57 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 263.57M | 197.67M | 141.05M | 49.01M | 71.45M | |
| Enterprise value | 197.58M | 145.21M | 100.06M | 19.6M | 218.53K | |
| P/E ratio | -6.52 | -4.38 | -3.57 | -1.28 | -2.08 | |
| Price to sales ratio | 1.35K | 2K | 668.48 | 161.23 | 179.98 | |
| POCF ratio | -26.99 | -16.3 | -12.91 | -5 | -7.19 | |
| PFCF ratio | -26.99 | -11.8 | -12.91 | -5 | -7.19 | |
| P/B Ratio | 1.34 | 1.07 | 0.81 | 0.23 | 0.34 | |
| PTB ratio | 1.34 | 1.07 | 0.81 | 0.23 | 0.34 | |
| EV to sales | 1.01K | 1.47K | 474.21 | 64.47 | 0.55 | |
| Enterprise value over EBITDA | -19.72 | -12.96 | -10.24 | -2.07 | -0.03 | |
| EV to operating cash flow | -20.23 | -11.97 | -9.16 | -2 | -0.02 | |
| EV to free cash flow | -20.23 | -8.67 | -9.16 | -2 | -0.02 | |
| Earnings yield | -0.04 | -0.06 | -0.07 | -0.2 | -0.12 | |
| Free cash flow yield | -0.04 | -0.08 | -0.08 | -0.2 | -0.14 | |
| Debt to equity | 0.04 | 0.04 | 0.03 | 0.06 | 0.02 | |
| Debt to assets | 0.03 | 0.04 | 0.03 | 0.06 | 0.02 | |
| Net debt to EBITDA | 6.59 | 4.68 | 4.2 | 3.11 | 8.44 | |
| Current ratio | 9.54 | 7.98 | 7.52 | 5.36 | 17.11 | |
| Interest coverage | 0 | 0 | -450.09 | -563.59 | -141.89 | |
| Income quality | 0.97 | 1.07 | 1.11 | 1.03 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 8.35 | 18.43 | 9.65 | 7.76 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.66 | 0.71 | 0.76 | 0.6 | 0.65 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.13 | 5.26 | 4.79 | 5.1 | 2.47 | |
| ROIC | -0.15 | -0.14 | -0.1 | -0.06 | -0.13 | |
| Return on tangible assets | -0.15 | -0.2 | -0.22 | -0.1 | -0.12 | |
| Graham Net | 1.43 | 1.11 | 0.86 | 0.39 | 0.82 | |
| Working capital | 60.18M | 47.58M | 37.24M | 56.21M | 68.98M | |
| Tangible asset value | 61.16M | 48.65M | 38.23M | 78.43M | 69.92M | |
| Net current asset value | 60.18M | 47.58M | 37.24M | 56.21M | 68.98M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 4.13M | 3.88M | 2.7M | 2.07M | 1.92M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 62.98 | 59.64 | 34.48 | 66.24 | 31.59 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.43 | 1.51 | 2.61 | 1.36 | 2.85 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.05 | -0.06 | -0.06 | -0.04 | -0.04 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
SPAGO.ST Frequently Asked Questions
What is Spago Nanomedical AB (publ) stock symbol ?
Spago Nanomedical AB (publ) is a SE stock and trading under the symbol SPAGO.ST
What is Spago Nanomedical AB (publ) stock quote today ?
Spago Nanomedical AB (publ) stock price is $0.81 today.
Is Spago Nanomedical AB (publ) stock public?
Yes, Spago Nanomedical AB (publ) is a publicly traded company.
Company Profile
- Volume Average 105.63K
- Market Capitalization 78.38M
- Employee 15
- CEO Dr. Mats Hansen M.Sc., Ph.D.
- Headquarters Lund,SE
- IPO Date 2013-01-16
-
Website
https://spagonanomedical.se 
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
